Modulators of indoleamine 2,3-dioxygenase

Patent metadata

Field	Value
Publication number	US-10538495-B2
Application number	US-201716094910-A
Country	US
Kind code	B2
Filing date	May 11, 2017
Priority date	May 12, 2016
Publication date	Jan 21, 2020
Grant date	Jan 21, 2020

Abstract

Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases.

First claim

What is claimed is:

1. A compound of Formula II

or a pharmaceutically acceptable salt thereof, wherein
in each depicted ring containing Xs, either each X is CH to form a benzene ring, or one X is N while the others are CH to form a pyridine ring;
the depicted tetrazole may optionally be substituted by a CH 2 OH, wherein said CH 2 OH is optionally converted into a prodrug by converting the CH 2 OH group to a CH 2 OC(O)CH 3 , CH 2 OC(O)C(C 1-4 alkyl) 3 , or OP(O)(OH) 2 group, or OP(O)(OC 1-4 alkyl) 2 group;
R 3 is phenyl, or a 4 to 6-membered heterocycle or heteroaryl containing 1 to 4 heteroatoms selected from N, S, and O; and wherein said phenyl, heterocycle, or heteroaryl, may optionally substituted by one to three C 1-3 alkyl groups each of which is optionally substituted by 1-3 halogens.

2. A pharmaceutical composition comprising a compound or salt according to claim 1 .

Assignees

• Glaxosmithkline Ip Dev Ltd

Inventors

• Johns Brian Alvin
• Kazmierski Wieslaw Mieczyslaw
• De La Rosa Martha Alicia
• Samano Vicente

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/18

  for HIV · CPC title